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Abstract. SCC VII tumor-bearing mice were continuously
given 5-bromo-2'-deoxyuridine (BrdU) to label all intratumor
proliferating (P) cells. They received hexamethylenetetramine
(HMTA) either once intraperitoneally or continuously
subcutaneously together with chemotherapy using intra-
peritoneally administered free doxorubicin (DXR) or intra-
venously injected pegylated liposomal doxorubicin (PLD).
One hour after the free DXR loading or 24 h after the PLD
loading, the response of intratumor quiescent (Q) cells was
assessed in terms of the micronucleus frequency using
immunofluorescence staining for BrdU. The response of the
total (P + Q) tumor cell population was determined from the
tumors not treated with BrdU. Encapsulation of DXR into
pegylated liposomes significantly enhanced cytotoxicity,
especially in Q cells. HMTA, especially when administered
continuously, efficiently increased the sensitivity to DXR,
particularly in Q cells. The increase in sensitivity on the
continuous rather than single administration of HMTA was a
little clearer in the total cell population than in Q cells. DXR's
encapsulation into pegylated liposomes and combination
with HMTA, particularly when administered continuously,
apparently reduced the difference in sensitivity to free DXR
between the total and Q cell populations. In terms of the tumor
cell-killing effect as a whole, including Q cells, the encap-
sulation of DXR into pegylated liposomes and combination
with HMTA, particularly through continuous administration,
are very promising, taking into account that HMTA has been
used clinically.
Introduction
Pegylated liposomal doxorubicin (PLD) is a liposomal
formulation of doxorubicin, reducing uptake by the reticulo-
endothelial system due to the attachment of polyethylene
glycol polymers to a lipid anchor and stably retaining drugs
as a result of liposomal entrapment via an ammonium sulfate
chemical gradient (1). These features result in a pharmaco-
kinetic profile characterized by an extended circulation time
and a reduced volume of distribution, thereby promoting tumor
uptake. Studies of tissue distribution indicated preferential
accumulation into various implanted tumors and human tumor
xenografts, with an enhancement of drug concentrations in
the tumor when compared with conventional free doxorubicin
(DXR) (1,2). Clinical studies of PLD in humans have included
patients with AIDS-related Kaposi's sarcoma and with a
variety of solid tumors, including ovarian, breast and prostate
carcinomas (2).
Formaldehyde preserves or fixes tissues or cells by
irreversibly cross-linking primary amine groups in proteins
with other nearby nitrogen atoms in protein or DNA through
a -CH2- linkage (3). An acid-dependent formaldehyde donor,
hexamethylenetetramine (HMTA) (Fig. 1), has been used as
an antiseptic for urinary tract infections and characterized as
a non-carcinogen in animals (3). Under hypoxic conditions in
solid tumors, pyruvate generated by glycolysis creates a low
pH environment that produces formaldehyde through
dissociation of HMTA (4). Actually, based on the finding
that HMTA released six molecules of formaldehyde in a
pH-dependent manner, DXR was shown to react with
formaldehyde to yield an activated form of DXR that can
further react with DNA to yield DXR-DNA adducts (4).
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Many cells in solid tumors are quiescent in situ but still
clonogenic (5). Quiescent (Q) tumor cells are more resistant
to radiation and conventional chemotherapy because of a
larger hypoxic fraction and greater capacity to recover from
potentially lethal damage than proliferating (P) tumor cells.
In this study, with our method for selectively detecting the
response of Q cells within solid tumors (6), we investigated
whether HMTA has selective killing effects on the intra-
tumor hypoxia-rich Q cell population, compared with the total
(P + Q) tumor cell population. In addition, the usefulness of
continuous administration of HMTA was also evaluated (7).
Actually, this study is one of the very few attempts to assess
the effectiveness of HMTA as a systemic anti-tumor agent
in vivo.
Materials and methods
Mice and tumors. SCC VII squamous cell carcinomas
(Department of Radiotherapy, Kyoto University) derived from
C3H/He mice were maintained in vitro in Eagle's minimum
essential medium supplemented with 12.5% fetal bovine
serum. The cells (1.0x105) were inoculated subcutaneously
into both hind legs of 8- to 11-week-old syngeneic female
C3H/He mice (Japan Animal Co., Ltd., Osaka, Japan).
Fourteen days later, each tumor ~1 cm in diameter was
employed for experiments and the body weight of the tumor-
bearing mice was 22.1±2.3 g (mean ± SD). Mice were handled
according to the Recommendations for Handling of Laboratory
Animals for Biomedical Research, compiled by the Committee
on Safety and Ethical Handling Regulations for Laboratory
Animal Experiments, Kyoto University. Incidentally, the p53
of SCC VII tumor cells is the wild-type (8).
Labeling with 5-bromo-2'-deoxyuridine (BrdU). Nine days
after the inoculation, mini-osmotic pumps (Durect Corporation,
Cupertino, CA) containing BrdU dissolved in physiological
saline (250 mg/ml) were implanted subcutaneously to label
all P cells for 5 days. The labeling index after continuous
labeling with BrdU was 55.3±4.5% and reached a plateau at
this stage. Therefore, we regarded tumor cells not incorporating
BrdU after continuous labeling as Q cells.
Preparation of pegylated liposomes encapsulating DXR (PLD).
Liposome hydrogenated soy phosphatidylcholine (HSPC),
cholesterol and distearoyl-phosphatidyl-ethanolamine
conjugated at its amino position with a 2000 molecular weight
segment of polyethylene glycol carbamate (PEG-2000-DSPE)
(56.7/38.2/5.1, mol%) (145.8 mg) were dissolved in chloroform
and the solvent was removed by evaporation. The obtained
thin lipid/copolymer-mixed membrane was further dried under
vacuum for 3 h and was dispersed in an aqueous (NH4)2SO4
solution (300 mM, 9 ml, pH 5.3). The liposome suspension
was extruded through a polycarbonate membrane with a pore
size of 100 nm and was applied to a Sepharose 4B column
equilibrated with 20 mM Hepes and 150 mM NaCl (pH 7.4).
Then, an aqueous DXR solution (10 mg/ml, 390 ml) was added
to the recovered liposome suspension (13.9 ml, 1.7 mM of
HSPC) and the mixed suspension was incubated for 1 h at
60˚C. The DXR-loaded liposomes were again purified using
a Sepharose 4B column with a mixture of 20 mM Hepes and
150 mM NaCl (pH 7.4) (9). Mean particle size was 138 nm.
DXR was obtained from Kyowa Hakko Kogyo Co., Ltd, Japan.
Treatment. After the labeling with BrdU, HMTA dissolved
in physiological saline was administered at a dose of
28.5 millimole/kg, singly by intraperitoneal injection or
continuously for 24 h by subcutaneously implanting mini-
osmotic pumps. The dose employed, yielding a surviving
fraction of ~0.5 on the single intraperitoneal administration
of HMTA only, was based on our previous study (10) and the
toxicity data on the Material Safety Data Sheet for HMTA
(intravenous, mouse, LD50 = 9200 mg/kg). One hour after the
intraperitoneal injection or after the 24-h continuous
subcutaneous infusion of HMTA, free DXR and PLD were
administered at a dose of 2.0 through 8.0 mg/kg (as a
concentration of DXR) intraperitoneally and intravenously
through the tail vein, respectively. The maximum tolerated dose
of free DXR is 8 mg/kg. One hour after the intraperitoneal
administration of free DXR or 24 h after the intravenous
administration of PLD, implanted tumors were excised. All
above-mentioned sequences and the timing of each treatment
were appropriate enough to function completely (1,2).
Immunofluorescence staining of BrdU-labeled cells and
micronucleus (MN) assay. Tumors excised from the mice
given BrdU were minced and trypsinized [0.05% trypsin and
0.02% ethylenediamine-tetraacetic acid (EDTA) in phosphate-
buffered saline (PBS), 37˚C, 15 min]. Tumor cell suspensions
were incubated for 72 h in tissue culture dishes containing
complete medium and 1.0 μg/ml of cytochalasin-B to inhibit
cytokinesis while allowing nuclear division and the cultures
were then trypsinized and cell suspensions were fixed. After
the centrifugation of fixed cell suspensions, the cell pellet
was resuspended with cold Carnoy's fixative (ethanol:acetic
acid = 3:1 in volume). The suspension was then placed on a
glass microscope slide and the sample was dried at room
temperature. The slides were treated with 2 M hydrochloric
acid for 60 min at room temperature to dissociate the
histones and partially denature the DNA. The slides were then
immersed in borax-borate buffer (pH 8.5) to neutralize the
acid. BrdU-labeled tumor cells were detected by indirect
immunofluorescence staining using monoclonal anti-BrdU
antibody (Becton-Dickinson, San Jose, CA) and fluorescein
isothiocyanate (FITC)-conjugated anti-mouse IgG antibody
(Sigma, St. Louis, MO). To observe the double staining of
tumor cells with green-emitting FITC and red-emitting
propidium iodide (PI), cells on the slides were treated with
PI (2 μg/ml in PBS) and monitored under a fluorescence
microscope.
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Figure 1. Chemical structure of hexamethylenetetramine (HMTA).
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The MN frequency in cells not labeled with BrdU could
be examined by counting the micronuclei in the binuclear
cells that showed only red fluorescence. The MN frequency
was defined as the ratio of the number of micronuclei in the
binuclear cells to the total number of binuclear cells observed
(6). The MN frequency was also shown to be a tool for
detecting sensitivity to chemotherapeutic agents (6).
The ratios obtained in tumors not pretreated with BrdU
indicated the MN frequency at all phases in the total tumor cell
population. More than 400 binuclear cells were counted to
determine the MN frequency.
Clonogenic cell survival assay. The clonogenic cell survival
assay was also performed in the mice given no BrdU using an
in vivo-in vitro assay method. Tumors were disaggregated by
stirring for 20 min at 37˚C in PBS containing 0.05% trypsin
and 0.02% EDTA. The cell yield was (4.5±1.1) x 107/g tumor
weight.
More than 3 tumor-bearing mice with a tumor at each
hind leg were used to assess each set of conditions and
each experiment was repeated twice. Namely, >6 mice (= 12
tumors) were used for each set of conditions. To examine the
differences between pairs of values, Student's t-test was used
when variances of the two groups could be assumed to be
equal; otherwise the Welch t-test was used. P-values are from
two-sided tests.
Results
The plating efficiency and MN frequency when no dose of
DXR was administered are shown in Table I. Plating efficiency
in the total cell population and MN frequency in both the total
and Q cell populations decreased and increased significantly
(P<0.05), respectively, in the following order; without HMTA,
with HMTA injected once intraperitoneally and with HMTA
infused continuously subcutaneously. The values of MN
frequency were significantly larger in the Q cell population
than in the total cell population under all conditions (P<0.05).
The clonogenic cell survival curves for total tumor cell
populations after free DXR (left panel) or PLD (right panel)
treatment with or without pre-treatment HMTA administration
are shown in Fig. 2. Overall, the sensitivity to DXR was
significantly increased with PLD rather than free DXR for all
conditions (P<0.05). Whether free DXR or PLD was employed,
the sensitivity to DXR was elevated in the following order;
without HMTA < with HMTA injected once intraperitoneally
< with HMTA infused continuously subcutaneously.
For baseline correction, we used the normalized MN
frequency to exclude the MN frequency in tumors not treated
with DXR. The normalized MN frequency was the MN
frequency in the tumors treated with free DXR or PLD minus
that in the tumors not treated with DXR. The normalized MN
frequencies of total and Q cell populations after free DXR
(left panel) or PLD (right panel) treatment with or without
pre-treatment HMTA administration are shown in Fig. 3. On
the whole, in both populations, the sensitivity to DXR was
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Table I. Plating efficiency and micronucleus frequency
without doxorubicin administration.
–––––––––––––––––––––––––––––––––––––––––––––––––
Total tumor cells Quiescent cells
–––––––––––––––––––––––––––––––––––––––––––––––––
Plating efficiency
Without HMTA 52.0±4.5a -
With HMTA i.p. 25.4±2.7 -
With HMTA cont. 18.2±1.9 -
Micronucleus frequency
Without HMTA 0.056±0.005 0.081±0.011
With HMTA i.p. 0.193±0.014 0.261±0.025
With HMTA cont. 0.287±0.029 0.383±0.034
–––––––––––––––––––––––––––––––––––––––––––––––––
HMTA, hexamethylenetetramine; i.p., single intraperitoneal
administration; cont., continuous subcutaneous administration and
amean ± standard deviation.
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 2. The clonogenic cell survival curves for the total tumor cell
population after free doxorubicin (DXR) (left panel) or pegylated liposomal
doxorubicin (PLD) (right panel) treatment with or without pre-treatment
hexamethylenetetramine (HMTA) administration. HMTA was administered
once intraperitoneally (i.p.) or continuously (cont.) subcutaneously for 24 h.
Bars represent standard deviations.
Figure 3. The normalized micronucleus frequencies of total and quiescent
cell populations after free doxorubicin (DXR) (left panel) or pegylated
liposomal doxorubicin (PLD) (right panel) treatment with or without pre-
treatment hexamethylenetetramine (HMTA) administration. HMTA was
administered once intraperitoneally (i.p.) or continuously (cont.) subcu-
taneously for 24 h. Bars represent standard deviations.
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significantly increased by PLD more than free DXR under
all conditions (P<0.05). Whether free DXR or PLD was
employed, in total and Q cell populations, the sensitivity
increased in the following order; without HMTA < with
HMTA injected once intraperitoneally < with HMTA infused
continuously subcutaneously.
To analyze the effect due to encapsulation into pegylated
liposomes, DXR dose-modifying factors for the administration
of PLD compared with free DXR were calculated using the
data shown in Figs. 2 and 3 (Table II). In both total and Q cell
populations, the sensitivity to DXR was significantly enhanced
>2-fold by the encapsulation (P<0.05), with or without HMTA.
However, the enhancement ratios were decreased, more
dramatically in Q cells, in the following order; without HMTA
> with HMTA injected once intraperitoneally > with HMTA
infused continuously subcutaneously.
To investigate the effect of a single intraperitoneal
injection or the continuous subcutaneous infusion of HMTA,
dose-modifying factors with versus without HMTA were
calculated using the data shown in Figs. 2 and 3 (Table III).
Whether free DXR or PLD was employed, in both total and
Q cell populations, sensitivity to DXR was significantly
enhanced (P<0.05) in the following order; without HMTA <
with HMTA injected once intraperitoneal < with HMTA
infused continuously subcutaneously. The enhancement was
more marked in the Q cell population and with the use of free
DXR than in the total cell population and with the use of
PLD, respectively. The enhancement due to continuous
administration compared with a single administration was
more prominent in the total cell population and with the use
of free DXR than in the Q cell population and with the use of
PLD, respectively.
To examine the difference in sensitivity between the total
and Q cell populations, dose-modifying factors, which
compare the doses of DXR necessary to obtain a normalized
MN frequency of 0.1 in Q cells with those in the total cell
population, were calculated using the data in Figs. 2 and 3
(Table IV). Overall, the difference in sensitivity was suppressed
on the use of PDL compared with free DXR. Whether free
DXR or PLD was employed, the difference in sensitivity
was reduced in the following order; without HMTA > with
HMTA injected once intraperitoneally > with HMTA infused
continuously subcutaneously.
Discussion
Formaldehyde is a naturally occurring biological compound
present in all tissues, cells and bodily fluids (3). It functions
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Table II. Enhancement due to encapsulation into pegylated liposomes.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
DXR only DXR+HMTA i.p. DXR+HMTA cont.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Surviving fraction = 0.5
Total cells 2.1 (2.0-2.2)b 1.9 (1.8-2.0) 1.8 (1.7-1.9)
Normalized micronucleus frequency = 0.1
Total cells 2.7 (2.55-2.85) 2.2 (2.1-2.3) 2.1 (2.0-2.2)
Quiescent cells 3.0 (2.9-3.1) 2.4 (2.3-2.5) 2.2 (2.1-2.3)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
DXR, doxorubicin; HMTA, hexamethylenetetramine; i.p., single intraperitoneal administration; cont., continuous subcutaneous administration.
aThe ratio of the dose of DXR necessary to obtain each end-point with conventional free DXR to that necessary to obtain each end-point with
DXR encapsulated into pegylated liposomes. bValues in parentheses are 95% confidence limits, determined using standard errors. When the
ranges of 95% confidence limits do not overlap between any two values, the difference between the values is considered significant (P<0.05).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table III. Enhancement due to combination with hexamethylenetetramine.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Conventional free DXR Pegylated liposomal DXR
–––––––––––––––––––––––––––– ––––––––––––––––––––––––––––––
+ HMTA i.p. + HMTA cont. + HMTA i.p. + HMTA cont.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Surviving fraction = 0.5
Total cells 1.4 (1.3-1.5)b 2.0 (1.9-2.1) 1.15 (1.1-1.2) 1.65 (1.55-1.75)
Normalized micronucleus frequency = 0.1
Total cells 1.35 (1.25-1.45) 2.0 (1.9-2.1) 1.15 (1.1-1.2) 1.55 (1.45-1.65)
Quiescent cells 1.55 (1.45-1.65) 2.1 (2.0-2.2) 1.3 (1.2-1.4) 1.65 (1.55-1.75)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
DXR, doxorubicin; HMTA, hexamethylenetetramine; i.p., single intraperitoneal administration; cont., continuous subcutaneous administration.
aThe ratio of the dose of DXR necessary to obtain each end-point without HMTA to that necessary to obtain each end-point in combination with
HMTA. bValues in parentheses are 95% confidence limits, determined using standard errors. When the ranges of 95% confidence limits do not
overlap between any two values, the difference between the values is considered significant (P<0.05).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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as a key intermediate in the ‘one-carbon pool’ used for the
biosynthesis of purines, thymidine and some amino acids. It
is usually rapidly metabolized by reduction, oxidation and
reduced glutathione-dependent pathways (3). However,
saturation in formaldehyde metabolism may lead to DNA
damage. It has been shown that cells exposed to formaldehyde
exhibit, as a major form of DNA damage, DNA-protein
crosslinks (11). In a limited oxygen environment, pyruvate
generated by glycolysis in the cell cytoplasm is preferentially
converted into lactic acid by lactate dehydrogenase, which
creates a low pH environment (pH 6.4-6.8) (12). Further,
through the Warburg effect, many cancer cells vigorously
consume glucose and preferentially produce lactic acid even
in the presence of adequate oxygen (12). Thus, due to the
extracellular acidic conditions adjacent to solid tumors, an
acid-dependent formaldehyde donor, HMTA, should dissociate
to release formaldehyde into nearby tissues. Moreover,
HMTA has been examined as an antiseptic for the treatment
of urinary tract infections, as well as being studied in patients
with maxillofacial phelegmons and as a prophylactic agent
against recurrent acute cystitis (3,4). It has also been elucidated
that HMTA is well tolerated, even at doses of up to 5 g/kg/day
(4,13). Previous studies have shown that DXR can react
with formaldehyde to yield an activated form of DXR that
can further react with DNA to yield DXR-DNA adducts (4).
Because HMTA is known to hydrolyze under cellular
conditions and release six molecules of formaldehyde in a
pH-dependent manner, we examined HMTA for its potential
as a formaldehyde-releasing prodrug for the activation of DXR
(4).
Based on our previous study (6) that the intratumor Q cell
population includes a much larger hypoxic fraction, where a
low pH environment is often created, than the total cell
population, more HMTA could be converted into formal-
dehyde in Q cell fraction, resulting in significantly larger MN
frequencies than in the total cell population when HMTA
only was administered (Table I). This also supports a more
marked enhancement by HMTA in Q cells than the total cell
population when DXR was co-administered (Table III).
PLD is characterized by an extended circulation time and
reduced volume of distribution (1,2). The extended circulation
time and the ability to extravasate through the leaky vasculature
of tumors result in the enhanced delivery of PLD to the tumor
site (1,2). Thus, the current study also showed an enhancement
ratio of >2.0 due to encapsulation into pegylated liposomes
(Table II), especially in resting Q cells where a clearer
enhancing effect due to the extended circulation time could be
observed than in the total cell population including P cells that
have strong uptake potential.
Tumor hypoxia results from either limited oxygen diffusion
(chronic hypoxia) or limited perfusion (acute hypoxia, transient
hypoxia or ischemic hypoxia) (5,6). Chronically hypoxic
tumor cells existing at the edge of the oxygen diffusion zone
can be killed by just a single administration of a hypoxic
cytotoxin. Acutely hypoxic tumor cells occurring sporadically
throughout solid tumors can be killed by a hypoxic cytotoxin
during long-term continuous administration. Namely, the
long-term continuous administration can kill both chronically
and acutely hypoxic tumor cells. Actually, it was already
shown that total and Q cell populations in SCC VII tumors
are rich in acutely and chronically hypoxic fractions,
respectively and that the continuous administration of the
hypoxic cytotoxin tirapazamine is very useful for sensitizing
tumor cells in vivo (7). Therefore, continuously administered
HMTA was also more cytotoxic to tumor cells in vivo than a
single intraperitoneal administration because the sensitizing
effect on the acutely hypoxia-rich total cell population was
added to the effect on the chronically hypoxia-rich Q cell
population. This is also why the enhancement due to
continuous administration compared with a single adminis-
tration was more marked in the total than Q cell population
(Table III). Furthermore, in both populations, the enhancement
in combination with HMTA was greater for free DXR than
PLD because the enhancement itself by the encapsulation of
DXR into pegylated liposomes was essentially very powerful
(Tables II and III).
Basically, the enhancement by the encapsulation of DXR
into pegylated liposomes and in combination with HMTA
through single or continuous administration was more dramatic
in the Q than total cell population. The enhancement in
combination with HMTA through continuous administration
compared with no combination was more marked in Q cells,
although the enhancement compared with a single admini-
stration was more remarkable in the total cell population
(Table III). Thus, the difference in sensitivity between the total
and Q cell populations was reduced with the use of PLD and
in combination with HMTA, especially when administered
continuously (Table IV). The presence of Q cells is thought to
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Table IV. Dose-modifying factors for quiescent cells relative to the total tumor cell population.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
DXR only DXR+HMTA i.p. DXR+HMTA cont.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Normalized micronucleus frequency = 0.1
Conventinal free DXR 1.9 (1.75-2.05)b 1.7 (1.6-1.8) 1.6 (1.5-1.6)
Pegylated liposomal DXR 1.75 (1.65-1.85) 1.6 (1.5-1.7) 1.5 (1.4-1.6)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
DXR, doxorubicin; HMTA, hexamethylenetetramine; i.p., single intraperitoneal administration; cont., continuous subcutaneous administration.
aThe ratio of the dose of DXR necessary to obtain each normalized micronucleus frequency in quiescent cells to that necessary to obtain each
normalized micronucleus frequency in the total tumor cell population. bValues in parentheses are 95% confidence limits, determined using
standard errors. When the ranges of 95% confidence limits do not overlap between any two values, the difference between the values is
considered significant (P<0.05).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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be due, in part, to hypoxia and the depletion of nutrition in the
tumor core and this is another consequence of poor vascular
supply (5). This might promote the formation of micronuclei
in Q tumor cells even without the administration of DXR
(Table I). Essentially, Q cells showed less sensitivity to
DXR, similar to many other conventional chemotherapeutic
agents (6). This means that more Q cells can survive after
conventional chemotherapy than P cells. Thus, the control of
Q cells has a great impact on the outcome of anti-cancer
chemotherapy. Taking into account that HMTA has a history
of clinical use as an antiseptic for urinary tract infections
(4,13), it may have the potential to be employed together with
conventional chemotherapy. However, studies on the toxicity
of HMTA in normal tissues still have to be carried out for
safety assurance. In terms of the tumor cell-killing effect as a
whole, including intratumor Q cell control, encapsulation of a
chemotherapeutic agent into pegylated liposomes and the
combined use of continuously administered HMTA may be a
promising treatment modality for refractory tumors because
of the efficient cytotoxic effects.
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